Category: NVAX

3rd Quarter 2017 – Growth Portfolio Update

3rd Quarter 2017 – Growth Portfolio Update

AXN – As mentioned in the recent Aoxing Pharmaceutical blog, I ended my position in this stock as the company announced a delisting of their common stock. The remaining proceeds have been reinvested into 22nd Century Group and TransEnterix Inc. OBCI – Continuing to hold steady in this growth stock as it tracks towards $6.…

Read More Read More